Abstracts

533 – Home CAB+RPV LA Support Sustained Persistence, Adherence & Viral Suppression in PWH With Challenges 

Background The Mobile Outreach Retention and Engagement (MORE) program at Whitman-Walker Health offers care navigation, transportation, and optional home injections for PWH initiating CAB+RPV LA with VL >200 copies/mL or no medical visit in < 6 months. MORE previously demonstrated promising 4-month outcomes; this analysis evaluates the durability of these results at 10 months (M10). Methods…

276 – Robust HIV-Specific CD4+ and CD8+ T-Cell Responses in Chronic Progressors on Long-Term ART

Background HIV-1 infection in chronic progressors (CPs) is characterized by dysfunctional HIV-specific T cell responses. HIV controllers (HICs) maintain superior HIV-specific T cell responses that control viral replication. Recent studies have shown that long-term antiretroviral therapy (ART) is associated with dominant HIV-specific CD8+ T cell clonotypes displaying signatures of stemness. We compared the proliferative capacity…

1027 – Feasibility and Acceptability of Cervico-Vaginal Self-Sampling for STI Testing in Nairobi Pharmacies

Background Sexually transmitted infections (STIs) remain a global public health challenge with the highest burden in low-resource settings where limited screening causes delayed diagnosis and continued transmission. The World Health Organization estimates over 1 million curable STIs occur daily.Human papillomavirus (HPV) is the most common, with high-risk types such as 16, 18, 31, 33, 45,…

294 – AAV-Delivered Antibody Reaches Mucosal Sites and Protects Against SHIV Infection in Rhesus Macaques

Background Long-term delivery of potent and broadly neutralizing antibodies (bNAbs) via adeno-associated virus (AAV) vectors offers a promising strategy for HIV prevention. Methods Four Indian-origin rhesus macaques received a one-time intramuscular administration of AAV9 encoding bNAb PCIN63, a CD4 binding site antibody with the hallmark VRC01-class features and similar neutralization breadth but with significantly less…

312 – HIV-1 Envelope x CD3 DART® Molecules Do Not Induce GALT Inflammatory Markers in Persons With HIV-1

Background MGD014 and MGD020 are bispecific DART® molecules that bind CD3 and bind HIV-1 Env with specificities derived from non-neutralizing mAbs A32 and 7B2, respectively. They redirect CD3+ T lymphocytes to kill HIV-1-infected, Env-expressing CD4+ T cells. When administered to HIV-1-infected humanized mice on ART, the combination of MGD020+MGD014 reduced cell-associated viral RNA in tissues…

903 – Quantifying Uncertainty in HIV Transmission Risk From Persons With Low-Level Viremia

Background Recent WHO guidance states that individuals with low-level viremia (LLV, 200 – 1000 copies/mL) have “negligible” risk of HIV transmission, a modification of “undetectable = untransmittable” guidance. However, LLV is less stable than viral load (VL) that is undetectable, and no recent studies have rigorously quantified the resultant transmission risk. Here, we use updated…

760 – Depression and Suicidality Among People With Pulmonary Tuberculosis in East Africa

Background Depression is understudied among people with TB or TB/HIV co-infection in settings highly affected by these syndemic conditions. We investigated the prevalence of depression and suicidal thinking, and associated clinical and social factors, in people with pulmonary TB in East Africa. Methods This study was conducted in the Tuberculosis Sentinel Research Network of the…